These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1205 related items for PubMed ID: 25792448

  • 1. Overview of the new oral anticoagulants: opportunities and challenges.
    Yeh CH, Hogg K, Weitz JI.
    Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1056-65. PubMed ID: 25792448
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
    Bauer KA.
    Stroke; 2013 Jun; 44(6 Suppl 1):S38-40. PubMed ID: 23709725
    [No Abstract] [Full Text] [Related]

  • 6. [Thromboembolic prophylaxis 2011: is warfarin on the wane?].
    Di Pasquale G, Riva L.
    G Ital Cardiol (Rome); 2011 Sep; 12(9):556-65. PubMed ID: 21892216
    [Abstract] [Full Text] [Related]

  • 7. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T, Cotté FE, Gaudin AF, Kachaner I, Kongnakorn T, Durand-Zaleski I.
    J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
    [Abstract] [Full Text] [Related]

  • 8. Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
    Douketis J, Bell AD, Eikelboom J, Liew A.
    Can Fam Physician; 2014 Nov; 60(11):989-95. PubMed ID: 25392438
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Oral anticoagulants for stroke prevention in atrial fibrillation.
    Senoo K, Lane DA, Lip GY.
    Curr Probl Cardiol; 2014 Sep; 39(9):319-44. PubMed ID: 25194766
    [Abstract] [Full Text] [Related]

  • 13. Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.
    Eikelboom JW, Quinlan DJ, Hirsh J, Connolly SJ, Weitz JI.
    JAMA Cardiol; 2017 May 01; 2(5):566-574. PubMed ID: 28355459
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice.
    Gonzalez-Quesada CJ, Giugliano RP.
    Am J Cardiovasc Drugs; 2014 Apr 01; 14(2):111-27. PubMed ID: 24504768
    [Abstract] [Full Text] [Related]

  • 17. A review of oral anticoagulants in patients with atrial fibrillation.
    Greenspon AJ.
    Postgrad Med; 2012 Nov 01; 124(6):7-16. PubMed ID: 23322134
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY, Kongnakorn T, Phatak H, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Dorian P.
    Clin Ther; 2014 Feb 01; 36(2):192-210.e20. PubMed ID: 24508420
    [Abstract] [Full Text] [Related]

  • 19. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW, Barillari G.
    J Clin Pharm Ther; 2014 Apr 01; 39(2):118-35. PubMed ID: 24383983
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 61.